Study Title
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study Number
SCRI 61186372NSC2012 (COPERNICUS)
Enrollment status
Open
Categories
1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence, Lung Cancer, Non-Small Cell Lung Cancer
Study Summary
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Study Teaser
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS)
Study Coordinator
- Angie, 309-243-3613, aearles@illinoiscancercare.com
- Heather, 309-243-3661 hthulean@illinoiscancercare.com
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
Study Link
View Study DetailsComments
Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washington